Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
Phase of Trial: Phase I/II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Aderbasib (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 03 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 07 Dec 2016 Planned End Date changed from 1 May 2017 to 1 May 2018.